Christof Langer received an international engineering degree in food- and biotechnology (MSc) from the Vienna University of Applied Sciences in 1996 as well as an MBA in 2010. He started his professional career at Baxter BioScience where he held various leading positions in the area of pharmaceutical production. In 2004, he started up and lead Baxter´s newly built vaccines entity Baxter s.r.o. in the Czech Republic. As of 2006, he took responsibility as Managing Director in Switzerland for Baxter’s blockbuster biologics manufacturing facility. Back in Austria, he joined the allergy-focused biotech start-up S-TARget therapeutics in 2010 as co-founder. Together with Geert Mudde he co-founded OncoQR ML in 2013.
Geert C. Mudde
Geert C. Mudde received a Ph.D. in immunology from the University of Utrecht in 1985 and started his international professional career at the Swiss Institute for Asthma and Allergy Research in Davos in 1989. In 1992 he joined the pharmaceutical/biotechnology industry, where he held several senior management positions at the Novartis Research Institute in Vienna, Austria, at the Parke Davis Research Institute in Fresnes, France, at Ingenium Pharmaceuticals, Martinsried, Germany and at igeneon in Austria. In 2006, while joining Baxter BioScience in Vienna, he also co-founded the biotech company f-star, where he served as CSO until the foundation of the allergy-focused biotech start-up S-TARget therapeutics in 2010. Together with Christof Langer he co-founded OncoQR ML in 2013.